Third Rock Ventures | Activity | F4

Third Rock Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

insitro announced a strategic collaboration with AstraZeneca for AI-enabled discovery of novel therapeutics for MASH and cardiomyopathies.

Insitro

Insitro Third Rock Ventures

thirdrockventures.comOCT 15, 2026

OCT 15, 2026

Milestone

Revolution Medicines received FDA approval for RASONQUE (daraxonrasib), the first broad RAS-targeted medicine in metastatic pancreatic cancer.

Revolution Medicines

Revolution Medicines Third Rock Ventures

ir.revmed.comOCT 1, 2026

OCT 1, 2026

Exit

Lisata Therapeutics announced acquisition of Marea Therapeutics and $225 million concurrent private placement.

Marea Therapeutics

Marea Therapeutics Third Rock Ventures

thirdrockventures.comSEP 17, 2026

SEP 17, 2026

Investment

Led Flare Therapeutics' $85M insider-led Series C to advance FX-111, a first-in-class AR ON degrader for prostate cancer.

Flare Therapeutics

Flare Therapeutics Third Rock Ventures

flaretx.comJUN 30, 2026

globenewswire.com

thirdrockventures.com

JUN 30, 2026

Milestone

Trace Neuroscience initiated global clinical development program for TRCN-1023, an antisense oligonucleotide designed to restore UNC13A function for ALS treatment.

Trace Neuroscience

Trace Neuroscience Third Rock Ventures

thirdrockventures.comJUN 22, 2026

JUN 22, 2026

Milestone

Tango Therapeutics announced pricing of $600 million upsized public offering.

Tango Therapeutics

Tango Therapeutics Third Rock Ventures

thirdrockventures.comJUN 9, 2026

JUN 9, 2026

New Fund

Third Rock Ventures is targeting $750 million for its seventh fund, down from the $1.1 billion Fund VI raised in 2022.

Third Rock Ventures

Third Rock VenturesThird Rock Ventures

bizjournals.comJUN 8, 2026

JUN 8, 2026

Milestone

Terremoto Biosciences granted FDA Fast Track designation for TER-2013, an AKT1-selective small molecule inhibitor for breast cancer.

Terremoto Biosciences

Terremoto Biosciences Third Rock Ventures

thirdrockventures.comJUN 3, 2026

JUN 3, 2026

New Fund

Third Rock Ventures filed to raise its seventh fund targeting $750M, down from the $1.1B raised for Fund VI.

Third Rock Ventures Fund VII

Third Rock Ventures

bizjournals.comJUN 2026

JUN 2026

Exit

Portfolio company Candid Therapeutics agreed to be acquired by UCB for up to $2.2B in a T-cell engager bispecifics deal for autoimmune diseases.

Candid Therapeutics

Candid Therapeutics Third Rock Ventures

biopharmadive.comMAY 3, 2026

thirdrockventures.com

MAY 3, 2026

Milestone

Maze Therapeutics announced $150 million registered offering.

Maze Therapeutics

Maze Therapeutics Third Rock Ventures

thirdrockventures.comAPR 22, 2026

APR 22, 2026

Investment

Led Terremoto Biosciences' $108M Series C to advance selective AKT1-inhibitors in oncology and hereditary hemorrhagic telangiectasia.

Terremoto Biosciences

Terremoto Biosciences Third Rock Ventures

thirdrockventures.comAPR 15, 2026

APR 15, 2026

Milestone

Portfolio company Seaport Therapeutics filed to go public in April 2026.

Seaport Therapeutics

Seaport Therapeutics Third Rock Ventures

bizjournals.comAPR 2026

APR 2026

Exit

Candid Therapeutics merged with Rallybio Corporation in March 2026.

Candid Therapeutics

Candid Therapeutics Third Rock Ventures

thirdrockventures.comMAR 2026

MAR 2026

Page 1 of 2